Published in BMJ on April 19, 2003
Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol (2006) 1.44
The need for randomised controlled trials in urogynaecology. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.40
Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model. J Urol (2010) 1.17
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One (2011) 1.16
Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc (2008) 1.07
BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol (2009) 1.03
Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol (2006) 1.03
Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.98
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol (2011) 0.92
Bladder dysfunction in diabetes mellitus. Front Pharmacol (2010) 0.90
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag (2013) 0.90
Implantable Devices for Sustained, Intravesical Drug Delivery. Int Neurourol J (2016) 0.90
Pharmacologic management of overactive bladder. Clin Interv Aging (2007) 0.88
Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther (2007) 0.88
In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol (2009) 0.87
Management of overactive bladder. Nat Rev Urol (2010) 0.85
Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis. Ont Health Technol Assess Ser (2005) 0.84
Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract (2008) 0.84
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.84
Regenerative medicine based applications to combat stress urinary incontinence. World J Stem Cells (2013) 0.84
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol (2009) 0.84
Bladder sensory desensitization decreases urinary urgency. BMC Urol (2007) 0.82
Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.81
Experience with imidafenacin in the management of overactive bladder disorder. Ther Adv Urol (2013) 0.80
Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.80
Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness method. BMJ Open (2014) 0.79
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract (2007) 0.79
A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf (2012) 0.79
Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr (2016) 0.79
Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.78
Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial. PLoS One (2016) 0.78
Chiropractic care of interstitial cystitis/painful bladder syndrome associated with pelvic lumbar spine dysfunction: a case series. J Chiropr Med (2012) 0.77
Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol (2011) 0.77
Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag (2005) 0.76
Management of urinary incontinence. P T (2012) 0.76
Anti-diuresis in the management of daytime urinary -incontinence. Facts Views Vis Obgyn (2009) 0.75
Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.75
[Not Available]. Can Urol Assoc J (2014) 0.75
Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment. Investig Clin Urol (2017) 0.75
Anticholinergics reduce symptoms of overactive bladder. J Fam Pract (2003) 0.75
Behavioural approaches are helpful in overactive bladder. BMJ (2003) 0.75
Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS One (2017) 0.75
Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial. Int J Clin Exp Med (2014) 0.75
Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women. J Family Reprod Health (2014) 0.75
Medical management of overactive bladder. Indian J Urol (2010) 0.75
Cocaine- and amphetamine-regulated transcript peptide (CARTp): distribution and function in rat urinary bladder. J Mol Neurosci (2014) 0.75
A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. Med Sci Monit (2016) 0.75
Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults. World J Urol (2011) 0.75
Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.75
Urogynaecological research: current and future developments. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.75
Pharmacotherapy of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.75
Considerations for the management of urgency symptoms in patients with overactive bladder syndrome. World J Urol (2009) 0.75
What are pragmatic trials? BMJ (1998) 7.93
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int (2001) 5.10
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol (1999) 3.19
The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract (2001) 1.95
The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet Gynecol Scand (2000) 1.63
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (2002) 1.60
Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int J Urol (2000) 1.38
Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society. Neurourol Urodyn (1998) 1.34
Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol (1999) 1.32
The patient with an overactive bladder--symptoms and quality-of-life issues. Urology (1997) 1.25
Economic considerations and outcome measurement in urge incontinence. Urology (1997) 1.17
Extensive hematopoietic stem cell generation in the AGM region via maturation of VE-cadherin+CD45+ pre-definitive HSCs. Cell Stem Cell (2008) 2.43
Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev (2010) 1.94
Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int (2007) 1.70
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer (2006) 1.21
Adjustment of meta-analyses on the basis of quality scores should be abandoned. J Clin Epidemiol (2006) 1.16
Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev (2012) 1.08
Water quality monitoring: a combined approach to investigate gradients of change in the Great Barrier Reef, Australia. Mar Pollut Bull (2005) 1.08
Mouse extraembryonic arterial vessels harbor precursors capable of maturing into definitive HSCs. Blood (2013) 1.07
How important is TVT location? Acta Obstet Gynecol Scand (2004) 1.05
Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol (2008) 0.97
Does the tension-free vaginal tape stay where you put it? Am J Obstet Gynecol (2003) 0.94
Meta-analyses of small numbers of trials often agree with longer-term results. J Clin Epidemiol (2010) 0.92
Voiding function after tension-free vaginal tape: a longitudinal study. Aust N Z J Obstet Gynaecol (2004) 0.90
Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study. J Clin Epidemiol (2011) 0.90
Depression among older people with cognitive impairment: prevalence and detection. Int J Geriatr Psychiatry (2006) 0.85
Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: a short version Cochrane systematic review with meta-analysis. Neurourol Urodyn (2014) 0.84
Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int (2005) 0.83
Restraint and self-injury in people with intellectual disabilities: a review. J Intellect Disabil (2007) 0.77
Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.75
An antibody raised against in vitro-derived human mast cells identifies mature mast cells and a population of cells that are Fc epsilon RI(+), tryptase(-), and chymase(-) in a variety of human tissues. J Histochem Cytochem (2003) 0.75
Managing fatigue at work after traumatic brain injury: a qualitative descriptive study. Int J Rehabil Res (2022) 0.75
Women's experiences of doing long-term pelvic floor muscle exercises for the treatment of pelvic organ prolapse symptoms. Int Urogynecol J (2013) 0.75